Published • loading... • Updated
Weight-Loss Drugmaker Lilly Nears $1.97 Bn AtaiBeckley's Acquisition: Report
The deal would give Lilly access to AtaiBeckley’s Phase 3 DMT nasal spray for treatment-resistant depression, with shares jumping 66% after the report.
- On Thursday, Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, expanding its mental health treatment portfolio amid growing sector momentum.
- President Donald Trump's administration ordered faster regulatory reviews of psychedelic treatments and increased federal funding for their research, driving sector momentum.
- New York-based AtaiBeckley is developing BPL-003, a DMT-based nasal spray for treatment-resistant depression currently in Phase 3 clinical trials with results expected in 2029.
- The $6.75 per share acquisition price represents a 26% premium over AtaiBeckley's Wednesday close, reflecting Lilly's aggressive expansion strategy with over $10 billion committed to acquisitions this year.
- Lilly could pay an additional $1 billion if AtaiBeckley's drugs meet specific development and regulatory milestones, positioning the deal as a high-stakes bet on advanced-stage psychedelic treatments.
Insights by Ground AI
25 Articles
25 Articles
BT+2 Reposted by 2 other sources
The pharmaceutical company Eli Lilly announced on Thursday that the company is acquiring the pharmaceutical company AtaiBeckley.
·Borås, Sweden
Read Full Article
Eli Lilly concluded an agreement to acquire AtaiBeckley, a company focused on mental health, for an initial value of $2.8 billion, continuing the recent wave of pharmaceutical acquisitions. Exclusive material for subscribers. To have full access, access the link of the material and register.
·Rio de Janeiro, Brazil
Read Full Article
The Group thus secures access to advanced therapies for patients in whom conventional antidepressants do not work.
·Düsseldorf, Germany
Read Full Article
Coverage Details
Total News Sources25
Leaning Left2Leaning Right6Center5Last UpdatedBias Distribution46% Right
Bias Distribution
- 46% of the sources lean Right
46% Right
15%
C 39%
R 46%
Factuality
To view factuality data please Upgrade to Premium
